Q&A with OCRF Grantee John Weroha, MD, PhD
Q&A with OCRF Grantee John Weroha, MD, PhD
Q&A with John Weroha, MD, PhD 2014 Liz Tilberis Early Career Award Mayo Clinic Were you always in interested in science? By the … Continued
News
No Link Between Fertility Drugs and Breast, Ovarian and Ute...
No Link Between Fertility Drugs and Breast, Ovarian and Uterine Cancers
(July 1, 2014) There is “little evidence” that the use of conventional fertility hormones used for ovarian stimulation in the treatment of infertility increases the long-term risk of breast and … Continued
Palliative Care at Time of Cancer Diagnosis Improves Survival
Palliative Care at Time of Cancer Diagnosis Improves Survival
(June 25, 2014) Research presented at the annual meeting of the American Society of Clinical Oncology earlier this month suggests that palliative care delivered at the time of cancer diagnosis … Continued
Gemcitabine, Carboplatin, and Bevacizumab Extend PFS
Gemcitabine, Carboplatin, and Bevacizumab Extend PFS
(June 24, 2014) Earlier this month, researchers reported results of a Phase II trial which looked at efficacy and safety of a biweekly gemcitabine, carboplatin, and bevacizumab combination in patients … Continued
Webinar Highlights Research News from ASCO
Webinar Highlights Research News from ASCO
On Monday, June 16, 2014, Dr. Douglas Levine of Memorial Sloan Kettering Cancer Center presented a free webinar focusing on research news that was presented at 2014’s medical meetings. In … Continued
Report from the 2014 American Society of Clinical Oncology ...
Report from the 2014 American Society of Clinical Oncology Annual Meeting
Promising new combination treatments for ovarian cancer Dr. Joyce Liu, MD, on behalf of researchers from the National Cancer Institute (NCI) and Dana Farber Cancer Institute (DFCI), presented striking results … Continued
2014 ASCO Research Round-Up
2014 ASCO Research Round-Up
Posted by Laura Koontz on June 5, 2014 The 50th Annual Conference of the American Society of Clinical Oncology, held May 30 – June 3 in Chicago, featured a number of promising and thought … Continued
ASCO News: Two New Drugs Show Promise for Recurrent Ovarian...
ASCO News: Two New Drugs Show Promise for Recurrent Ovarian Cancer
(June 4, 2014) In a study presented at the American Society of Clinical Oncology annual meeting last week, researchers found that the combination of olaparib and cediranib (Recentin) kept recurrent … Continued
FDA Seeking Comments on Olaparib by June 11
FDA Seeking Comments on Olaparib by June 11
The Food and Drug Administration is seeking comments by June 11, 2014 on its review for Olaparib approval. Olaparib is an oral poly ADP-ribose polymerase (PARP) inhibitor that exploits DNA … Continued
Breastfeeding, Birth Control Pills May Reduce Ovarian Cance...
Breastfeeding, Birth Control Pills May Reduce Ovarian Cancer Risk Among Women with BRCA Gene Mutations
(May 16, 2014) Breastfeeding, tubal ligation – also known as having one’s “tubes tied” – and oral contraceptives may lower the risk of ovarian cancer for some women with BRCA … Continued
OCRF Research Shows How Ovarian Tumors Elude Immune System
OCRF Research Shows How Ovarian Tumors Elude Immune System
(May 6, 2014) Tumors use numerous mechanisms to escape detection and killing by the immune system. Results from OCRF-funded research, reported May 4, 2014 in the prestigious journal Nature Medicine, … Continued
Imaging Predicts Response in Ovarian Cancer
Imaging Predicts Response in Ovarian Cancer
(April 30, 2014) A positive pretreatment imaging test more than doubled the likelihood of disease control in platinum-resistant advanced ovarian cancer treated with the folate receptor-targeted drug vintafolide (trade name … Continued